Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)

The summary for the Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required): The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.
Federal Grant Title: Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Food and Nutrition Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-18-501
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.847
CFDA Descriptions: Information not provided
Current Application Deadline: November 20th, 2018
Original Application Deadline: November 20th, 2018
Posted Date: September 18th, 2018
Creation Date: September 18th, 2018
Archive Date: December 26th, 2018
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: September 18th, 2018
Applicants Eligible for this Grant
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: see the funding announcement for eligibility details
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-501.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...
Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...
Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...
Diabetes Research Centers (P30 Clinical Trial Optional)
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
Molecular Therapy Core Centers
Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health
Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com